News

Artificial Kidney Market Expected to Grow Amid Rising Kidney Disease Cases

• By John K. Waters
• 02/18/2025

The global artificial kidney market is projected to grow at a compound annual growth rate of approximately 13% by 2032, driven by increasing cases of chronic kidney disease (CKD) and end-stage renal disease (ESRD), according to a new report by DelveInsight Business Research.

The demand for advanced renal care solutions is growing as diabetes, hypertension, and aging populations contribute to rising kidney disease cases. The report highlights an increasing preference for home-based dialysis treatments and ongoing technological advancements in artificial kidney development as key factors shaping the market.

Market Trends and Key Players
According to DelveInsight, North America is expected to lead the artificial kidney market due to a well-established healthcare infrastructure and growing adoption of wearable and home dialysis technologies. Several companies, including Baxter, Fresenius Medical Care AG, Medtronic, and Quanta Dialysis Technologies, are actively involved in developing artificial kidney systems.
Recent industry developments include:

• Quanta Dialysis Technologies (September 2023) submitted a 510(k) premarket notification to the FDA for expanding the use of its Quanta™ Dialysis System to self-care and at-home hemodialysis.
• Fresenius Medical Care (August 2023) received FDA clearance for VersiHD with GuideMe Software, a redesigned home hemodialysis system.
• Medtronic and DaVita Inc. (April 2023) launched Mozarc Medical, a company focused on patient-centered kidney care technologies.

Challenges and Future Outlook
Although the artificial kidney market presents opportunities, challenges such as regulatory hurdles, high development costs, and clinical validation remain. Gaining approval from agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) requires extensive clinical trials.

Public-private partnerships are playing a role in advancing artificial kidney technology. In August 2022, the U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) launched the Kidney Innovation Accelerator (KidneyX) to accelerate the development of bioartificial kidneys.

Despite these hurdles, the shift toward more efficient, portable, and wearable kidney replacement devices is expected to improve patient quality of life and reduce dependence on dialysis. As research progresses, the artificial kidney market could play a significant role in reshaping kidney disease management worldwide.